Synonyms: AG-221 | CC-90007 | Idhifa®
enasidenib is an approved drug (FDA (2017))
Compound class:
Synthetic organic
Comment: Enasidenib (AG-221) is an orally available inhibitor of isocitrate dehygrogenase 2 (IDH2), that is approved as an antineoplastic agent. This compound is example 409 in patent US20130190287 A1 [1].
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2017)) |
Approved drug? | Yes. FDA (2017) |
IUPAC Name ![]() |
2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol |
International Nonproprietary Names ![]() |
|
INN number | INN |
10162 | enasidenib |
Synonyms ![]() |
AG-221 | CC-90007 | Idhifa® |
Database Links ![]() |
|
CAS Registry No. | 1446502-11-9 (source: WHO INN record) |
DrugCentral Ligand | 5251 |
GtoPdb PubChem SID | 310264741 |
PubChem CID | 89683805 |
RCSB PDB Ligand | 69Q |
Search Google for chemical match using the InChIKey | DYLUUSLLRIQKOE-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | DYLUUSLLRIQKOE |
Search PubMed clinical trials | enasidenib |
Search PubMed titles | enasidenib |
Search PubMed titles/abstracts | enasidenib |
UniChem Compound Search for chemical match using the InChIKey | DYLUUSLLRIQKOE-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | DYLUUSLLRIQKOE-UHFFFAOYSA-N |